Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
STAR-0310 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| STAR-0310 Dose 1 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 Dose 2 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 Dose 3 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 Dose 4 | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| STAR-0310 in Participants of Japanese Descent | EXPERIMENTAL | Participants will be randomized to receive STAR-0310 or matching placebo |
| Name | Type | Description |
|---|---|---|
| STAR-0310 | DRUG | STAR-0310 will be administered as a subcutaneous bolus injection. |
| Placebo | DRUG | Placebo will be administered as a subcutaneous bolus injection. |
Inclusion Criteria: * Good health as determined by the Investigator based upon a medical evaluation. * Body mass index (BMI) of 18 to 35 kg/m2 with a weight of at least 60 kg for men and at least 50 kg for women, with a maximum weight of 130 kg for any participant. * Participants of childbearing po...
STAR-0310 is an investigational small molecule being studied in healthy adult participants. It is currently in Phase 1 clinical development, with an active clinical trial evaluating its safety and tolerability. The drug is not yet approved and is still in the early stages of clinical research.
STAR-0310 targets OX40, a protein involved in immune responses. By targeting OX40, the drug may modulate immune system activity. However, its exact mechanism and therapeutic potential are still being investigated in early-stage clinical trials.
STAR-0310 is being developed by Astria Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ATXS. The company is conducting a Phase 1 clinical trial to evaluate the drug in healthy participants.
STAR-0310 is in Phase 1 clinical development. It is currently being studied in a randomized, double-blind, controlled trial involving healthy adult participants in the United States. The drug is investigational and has not yet received regulatory approval.
STAR-0310 is being evaluated in a Phase 1 clinical trial with the identifier NCT06782477, titled "A Study of STAR-0310 in Healthy Adult Participants." This active trial is enrolling 40 participants in the United States and is designed to assess the drug's safety and tolerability.